Abstract

Provided are: a stretched film made of ultrahigh-molecular-weight polyethylene, the stretched film including ultrahigh-molecular-weight polyethylene having a weight-average molecular weight, as estimated from a molecular-weight distribution curve of the contained polyethylenes obtained by gel permeation chromatography, of 500,000 or higher in an amount of 90 mass% or larger with respect to the whole mass of the stretched film made of ultrahigh-molecular-weight polyethylene, and having a tensile rupture strength of 300 MPa or higher and an elongation at rupture of 7% or higher; and a method for producing a stretched film made of a polyolefin.

IPC Classes  ?

• C08J 5/18 - Manufacture of films or sheets
• B29C 55/02 - Shaping by stretching, e.g. drawing through a dieApparatus therefor of plates or sheets
• C08F 2/00 - Processes of polymerisation
• C08F 4/60 - MetalsMetal hydridesMetallo-organic compoundsUse thereof as catalyst precursors selected from light metals, zinc, cadmium, mercury, copper, silver, gold, boron, gallium, indium, thallium, rare earths, or actinides together with refractory metals, iron group metals, platinum group metals, manganese, technetium, rhenium, or compounds thereof
• C08F 10/00 - Homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond

Abstract

The present invention provides: a carbon catalyst which has both high catalytic activity and high durability; an electrode; and a battery. The carbon catalyst has an L/La ratio of 18 or more, the L/La ratio being the ratio of the average carbon mesh surface size L, which is obtained by programmed-temperature desorption analysis in which the temperature can be increased to 1600°C, to the crystallite size La, which is obtained from a diffraction peak near a diffraction angle (2θ) of 43° in an X-ray diffraction pattern obtained by means of powder X-ray diffraction using a CuKα ray, and a ratio of the halogen atom concentration (atom%) to the carbon atom concentration (atom%) of 0.0005 or more as obtained by X-ray photoelectron spectroscopy.

IPC Classes  ?

• H01M 4/96 - Carbon-based electrodes
• B01J 27/24 - Nitrogen compounds
• B01J 35/60 - Catalysts, in general, characterised by their form or physical properties characterised by their surface properties or porosity
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/075 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound
• C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 12/06 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
• H01M 12/08 - Hybrid cellsManufacture thereof composed of a half-cell of a fuel-cell type and a half-cell of the secondary-cell type

Abstract

The present invention provides a vascular smooth muscle cell-tropic capsid which has an enhanced rate of infection to a vascular smooth muscle.　The present invention provides a capsid of an adeno-associated virus, the capsid being characterized in that a factor of tropism for vascular smooth muscle cells is added thereto. The factor of tropism is a peptide that is presented on the surface of a virus particle.　The peptide includes any one of "RENKLGE", "KDTVPRE", "TETGKTA", "STPAAKE", "RNREPTE", "ARNGTTE", "KDTAERQ", "NRGGNQD", "NRPDTNS", and "TRATSQE" in cases where vascular smooth muscle cells of a mouse (Mus musculus) are to be infected. The peptide includes any one of "NRPETNP", "SHDPSKE", "SEIRRDQ", "NRNKHEE", "RQDNKME", "THPPAPQ", "TRGGGSE", "TEKQTNS", "RVTMGSE", and "ATKNQNE" in cases where vascular smooth muscle cells of human (Homo sapiens) are to be infected.

IPC Classes  ?

• C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/34 - Proteins from DNA viruses
• C12N 15/864 - Parvoviral vectors
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

[Problem] To provide: a method for inexpensively producing a highly active oxygen carrier; a method for producing hydrogen using the highly active oxygen carrier; and an apparatus for producing hydrogen. [Solution] This method for producing an activated iron titanate-containing oxygen carrier which contains alkali titanate and iron oxide by firing a mixture of iron titanate particles and an alkali component is characterized in that the mixture of the iron titanate particles and the alkali component is prepared by physically mixing the iron titanate particles and an alkali compound, or by spraying or impregnating the iron titanate particles with an aqueous solution of the alkali compound and then drying the same.

IPC Classes  ?

• C01G 49/00 - Compounds of iron
• C01B 3/08 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of inorganic compounds containing electro-positively bound hydrogen, e.g. water, acids, bases, ammonia, with inorganic reducing agents with metals

Abstract

Provided are a carbon catalyst that exhibits high catalytic activity, an electrode, and a battery. The carbon catalyst has: a ratio L/La of at least 15, said L/La ratio being the ratio of the average carbon mesh surface size L, that was obtained by using temperature-programmed desorption analysis capable of raising the temperature to 1600°C, to the crystallite size La that was obtained from a diffraction peak near a diffraction angle (2θ) of 43° in an X-ray diffraction pattern obtained by means of powder X-ray diffraction using a CuKα ray; and a BET specific surface area of at least 100 m2/g.

IPC Classes  ?

• B01J 21/18 - Carbon
• B01J 35/60 - Catalysts, in general, characterised by their form or physical properties characterised by their surface properties or porosity
• B01J 35/77 - Compounds characterised by their crystallite size
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/075 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound
• H01M 4/90 - Selection of catalytic material
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 12/06 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
• H01M 12/08 - Hybrid cellsManufacture thereof composed of a half-cell of a fuel-cell type and a half-cell of the secondary-cell type

Abstract

Provided are: a carbon catalyst which exhibits high catalytic activity while effectively avoiding problems attributable to iron; an electrode; and a battery. The carbon catalyst has an L/La of 12 or greater, wherein the La is a crystallite size obtained from a diffraction peak at a diffraction angle (2θ) of about 43° in an X-ray diffraction pattern obtained by X-ray powder diffractometry with CuKα line and the L is an average carbon sheet size obtained by thermal desorption spectrometry capable of heating to 1600°C. The carbon catalyst has an iron content of 3,000 ppm or less.

IPC Classes  ?

• B01J 21/18 - Carbon
• B01J 35/60 - Catalysts, in general, characterised by their form or physical properties characterised by their surface properties or porosity
• B01J 35/77 - Compounds characterised by their crystallite size
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/075 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound
• H01M 4/90 - Selection of catalytic material
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 12/06 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
• H01M 12/08 - Hybrid cellsManufacture thereof composed of a half-cell of a fuel-cell type and a half-cell of the secondary-cell type

Abstract

The present invention is an estimation device (1) comprising an overvoltage calculation unit (20) for calculating the overvoltage of a battery (50) on the basis of a measured value for a current flowing through the battery (50) and a measured value for the terminal voltage of the battery (50), and an estimation unit (30) having a system identification unit and an effective resistance calculation unit, wherein the estimation device (1) is characterized in that the system identification unit identifies the system of the battery (50) by estimating the parameters of each term in a polynomial constituting an FIR model on the basis of time-series data pertaining to the current and the overvoltage, and the effective resistance calculation unit calculates the effective resistance on the basis of the system of the battery (50), the system identification unit dividing the polynomial constituting the FIR model into a plurality of time segments and estimating a common parameter with respect to the terms included in the respective time segments to thereby estimate a smaller number of parameters than the number of terms in the polynomial of the FIR model.

IPC Classes  ?

• G01R 31/367 - Software therefor, e.g. for battery testing using modelling or look-up tables
• G01R 31/3828 - Arrangements for monitoring battery or accumulator variables, e.g. SoC using current integration
• G01R 31/388 - Determining ampere-hour charge capacity or SoC involving voltage measurements
• G01R 31/389 - Measuring internal impedance, internal conductance or related variables
• H01M 10/48 - Accumulators combined with arrangements for measuring, testing or indicating the condition of cells, e.g. the level or density of the electrolyte
• H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries

Abstract

A novel drug for treating or preventing skin hardening in systemic scleroderma has been discovered due to the discovery that skin hardening in systemic scleroderma can be ameliorated by the administration of a sirolimus-containing topical drug to the skin.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions
• A61K 9/70 - Web, sheet or filament bases
• A61P 17/00 - Drugs for dermatological disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/28 - Tumor necrosis factors

Abstract

Provided are an ultra-high molecular weight polyethylene sheet, and a method for producing a polyolefin sheet, the method comprising a step A for applying an organic solvent containing a metal catalyst to the inner wall surface of a container, and a step B for synthesizing polyolefin on the inner wall surface of the container by introducing an olefin monomer into the container in which the inner wall surface is coated with the organic solvent containing a metal catalyst, wherein in the step A, the organic solvent containing a metal catalyst is applied to the inner wall surface of the container by moving the container.

IPC Classes  ?

• C08F 2/00 - Processes of polymerisation
• C08F 10/00 - Homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
• C08F 10/02 - Ethene
• C08J 5/18 - Manufacture of films or sheets

Abstract

An inhibitory neuron-specific promoter sequence is discovered, which has a shorter length compared with a mGAD65 promoter and is not deteriorated in all of a promoter activity, specificity to an inhibitory neuron and a gene expression efficiency. More specifically, a promoter is provided, which comprises DNA having a promoter activity, in which the DNA comprises a nucleotide sequence for a Dlx1 binding site and/or a Dlx2 binding site in a glutamic acid decarboxylase (GAD) promoter and a nucleotide sequence for a region lying between the 5'-terminal of exon 1 and a transcription start point (TSS) in a glutamic acid decarboxylase (GAD).

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material

Abstract

The present invention comprises: an introduction section that has a first solid-state device having a semiconductor quantum well structure, and into which a plurality of electron spin waves are introduced; a modulation section that has a second solid-state device having a semiconductor quantum well structure connected to the introduction section, and synthesizes the electron spin waves from the introduction section to generate multiple electron spin waves; and a separation section having a third solid-state device having a semiconductor quantum well structure connected to the modulation section, the multiple electron spin waves synthesized in the modulation section being introduced in the separation section, the separation section separating the plurality of electron spin waves from the multiple electron spin waves. The modulation section has the function of superposition of the plurality of electron spin waves by controlling the amplitude, phase, and polarization degrees of freedom of the electron spin waves using the permanent spin-swirling state in the crystal orientation dependence of the effective magnetic field due to spin-orbit interaction generated in the semiconductor quantum well structure.

IPC Classes  ?

• H04B 10/90 - Non-optical transmission systems, e.g. transmission systems employing non-photonic corpuscular radiation
• H04B 10/60 - Receivers

Abstract

In this magnetic levitation motor, an attraction force toward a one-side stator acts on a rotor, and an attraction force toward the other-side stator acts on the rotor, whereby the rotor is caused to levitate between the one-side stator and the other-side stator. Further, the rotor is rotated through control of supply of electric current to each winding of the other-side stator and control of the magnetic pole at the one-side surface of each salient pole of the other-side stator. Here, the one-side stator is provided with a permanent magnet, but is not provided with a winding. Thus, this motor can be provided by a simple configuration.

IPC Classes  ?

• H02K 21/24 - Synchronous motors having permanent magnetsSynchronous generators having permanent magnets with stationary armatures and rotating magnets with magnets axially facing the armatures, e.g. hub-type cycle dynamos
• H02K 7/09 - Structural association with bearings with magnetic bearings

Abstract

The present specification provides an antisense oligomer that has a length of 15-30 bases and that has a base sequence complementary to the base sequence of a target region, a pharmaceutically acceptable salt thereof, or a hydrate of the same. The target region has: a base sequence that is consecutive by at least 10 times and that is in at least one region selected from the group consisting of the 5' UTR region, the nsp1 region, the nsp10 region, the RNA-dependent RNA polymerase region, the ORF10 region, and the 3' UTR region in the genome RNA of SARS-CoV-2; or a sequence complementary to said base sequence. The antisense oligomer, or the pharmaceutically acceptable salt thereof, or the hydrate of the same has an antiviral effect with respect to a virus selected from the group consisting of SARS-CoV-2, SARS-CoV-1, and MERS-CoV.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• A61K 31/787 - Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/12 - Antivirals
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

The present invention addresses the problem of providing an antifungal eye drop, particularly, an aqueous eye drop, the eye drop containing luliconazole as an active ingredient. The problem is solved by the eye drop which contains: 1) luliconazole; 2) benzyl alcohol; and 3) one or two selected from polyoxyethylene polyoxypropylene glycol and polyoxyethylene hydrogenated castor oil.

IPC Classes  ?

• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 9/08 - Solutions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61P 27/02 - Ophthalmic agents
• A61P 31/10 - Antimycotics

Abstract

Provided is a method for manufacturing an oligofuran skeleton-containing polycarbosilane, comprising a polymerization step in which a dihydro-silyl oligofuran compound is reacted with a diene compound and/or a diyne compound in the presence of a hydrosilylation catalyst, wherein the dihydro-silyl oligofuran compound is a compound in which both terminal furan rings of a 2 to 256-mer of a monofuran compound has a hydrosilyl group at the α-position thereof.

IPC Classes  ?

• C08G 77/60 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon in which all the silicon atoms are connected by linkages other than oxygen atoms

Abstract

A method for producing a dihydrosilyloligofuran compound, comprising a deprotonization step in which an oligofuran compound is deprotonized in the presence of a deprotonization agent and a silylation step in which the product of deprotonization of the oligofuran compound is reacted with a hydrosilane compound, the oligofuran compound being a dimer to 256-mer of a monofuran compound.

IPC Classes  ?

• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

The present invention addresses the problem of developing a fluorescent reagent with which lipid droplets from the scale of cultured cells to the scale of an individual can be imaged at high sensitivity, and which can be used in combination with a green fluorescent protein. The present invention provides a reagent for detecting lipid droplets, the reagent containing a compound represented by formula (I). (In the formula, m represents an integer of 3-5, n represents an integer of 3-5, and R represents a C1-5 alkyl, a C6-12 aryl, a C7-13 aralkyl, or hydrogen.)

IPC Classes  ?

• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
• A61K 49/00 - Preparations for testing in vivo
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C09B 57/02 - Coumarine dyes
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

In the present description, provided are an antisense oligonucleotide targeting a specific region of the genomic RNA of SARS-CoV-2, a pharmaceutically acceptable salt thereof or a hydrate of the same, a pharmaceutical composition containing the antisense oligonucleotide, a pharmaceutically acceptable salt thereof or a hydrate of the same, etc.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/14 - Antivirals for RNA viruses

Abstract

By PCR using peptide nucleic acid (PNA), the present inventors have established a method for single nucleotide polymorphism examination including the detection of a missense mutation c.59T>G which is common in the recessive le allele of FUT3 gene (Le gene) possessed by Japanese people. Thus, the present inventors have successfully provided a rapid and simple method by which the presence or absence of the gene mutation participating in the sugar chain antigen production can be checked, in parallel with a CA19-9 test, at a clinical examination site.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6858 - Allele-specific amplification
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Provided are: a sub-micron thin film made of an ultra-high molecular weight polyethylene, the sub-micron thin film containing, as a main component, an ultra-high molecular weight polyethylene that has a viscosity average molecular weight of 1,000,000 to 15,000,000, and having a film thickness of less than 1 μm and a tensile strength at break of 100 MPa or higher; and a method for manufacturing the same.

IPC Classes  ?

• C08J 5/18 - Manufacture of films or sheets
• B29C 55/12 - Shaping by stretching, e.g. drawing through a dieApparatus therefor of plates or sheets multiaxial biaxial

Abstract

Provided is a composition for producing a parental-line animal/plant capable of producing and maintaining an epigenome-modified animal/plant.　A composition according to the present invention is employed in producing a parental-line animal/plant employed in producing or maintaining an epigenome-modified animal/plant, wherein: the composition contains nucleic acids; the nucleic acids contain nucleic acids coding for a nucleic-acid-sequence recognition module that specifically binds to a nucleic acid sequence in a target region, in which an epigenome modification is performed in a genomic DNA, and an epigenome modifying enzyme that is capable of modifying an epigenome; the sequence recognition module and the epigenome modifying enzyme can form a complex; the nucleic acids are configured so that, as a result of being functionally joined with a gametogenesis-specific promoter activated in a gametogenesis, the expressions of the sequence recognition module and the epigenome modifying enzyme are induced in the gametogenesis; and, in the gametogenesis, the nucleic-acid-sequence recognition module and the epigenome modifying enzyme, the expressions of which have been induced, form a complex and modify an epigenome in the target region in the genomic DNA of a gamete in the process of the gametogenesis.

IPC Classes  ?

• A01H 1/00 - Processes for modifying genotypes
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 19/00 - Hybrid peptides
• C12N 5/075 - OocytesOogonia
• C12N 5/076 - Sperm cellsSpermatogonia
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/54 - Transferases (2)
• C12N 15/55 - Hydrolases (3)
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

Provided is a biodegradable resin composition that can be used particularly for the production of a molded article having high marine biodegradability. In particular, provided is a biodegradable resin composition which contains a biodegradable resin and one or more components selected from the group consisting of agarose, sodium alginate, casein, and keratin, and has a biodegradable resin content of 50 wt% or greater.

IPC Classes  ?

• C08L 101/00 - Compositions of unspecified macromolecular compounds
• C08L 67/00 - Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chainCompositions of derivatives of such polymers
• C08L 101/16 - Compositions of unspecified macromolecular compounds the macromolecular compounds being biodegradable

Abstract

The present invention addresses the problem of providing: an antiviral nucleic acid, etc., against SARS-CoV-2 SARS-CoV-2, SARS-CoV-1, or MERS-CoV; and/or a method for treating and/or preventing a viral infection using the nucleic acid, etc.　The present invention relates to an antiviral nucleic acid that targets a sequence in at least one target region selected from the group consisting of the 5' UTR region, nsp3 region, 3C-like proteinase region, nsp9 region, RNA-dependent RNA polymerase region, helicase region, 3'-to-5' exonuclease region, 2'-O-ribose methyltransferase region, S region including S1 region and S2 region, E region, M region, and N region in the genomic RNA of SARS-CoV-2, or a pharmacologically acceptable salt thereof or a hydrate of these, etc., wherein the virus is SARS-CoV-2, SARS-CoV-1, or MERS-CoV.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/12 - Antivirals
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present invention addresses the problem of developing a novel reagent for blood vessel imaging that is easy to produce, highly sensitive and highly accurate. The present invention provides a reagent for blood vessel imaging that contains a compound comprising an oligoarginine represented by formula and a phosphor or fluorophore group bound to the C-terminal or N-terminal side of the oligoarginine.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• G01N 21/64 - FluorescencePhosphorescence

Abstract

The present invention addresses the problem of providing a recombinant antibody, a recombinant antibody derivative, or a drug composition including one or more of such antibodies which can be used to treat SARS-CoV2 virus infection by neutralizing infection by a SARS-CoV2 virus amplified inside the body due to a SARS-CoV2 virus infection.　As a result of rigorous examination, the inventors of the present invention have discovered a plurality of cells that produce antibodies against the SARS-CoV2 virus from bodies which have been infected with and recovered from the SARS-CoV2 virus in the past, and have shown that the aforementioned problem can be solved by making, from the aforementioned cells, antibodies or antibody derivatives that have the ability to bind to one or more SARS-CoV2 viruses and have the action of suppressing amplification of the SARS-CoV2 virus or neutralizing SARS-CoV2 virus infection.

IPC Classes  ?

• C12N 15/13 - Immunoglobulins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C07K 16/46 - Hybrid immunoglobulins
• C12P 21/08 - Monoclonal antibodies

Abstract

Provided is a blood measurement device that is capable of accurately estimating blood component amounts, by causing each light ray for calculating blood component amounts to pass along the same optical axis.　This blood measurement device 10 comprises: a light-emission unit 11 that has a first light-emission unit 111 and a second light-emission unit 112; a light-reception unit 19; an actuator 16; and a calculation control unit 17 that estimates the amount of glucose and controls the operation of the actuator 16. In addition, the calculation control unit 17 moves, by using the actuator 16, the light-emission point for the first light-emission unit 111 onto an optical axis 22 that is defined so as to penetrate a measurement site, when irradiating the first light ray on to the measurement site from the first light-emission unit 111. The calculation control unit 17 also moves the light-emission point for the second light-emission unit 112 on to the optical axis 22, by using the actuator 16, when irradiating the second light ray on the measurement site from the second light-emission unit 112.

IPC Classes  ?

• G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters

Abstract

Provided is a glucose amount calculation method which makes it possible to measure the amount of glucose accurately by statistically utilizing the intensity of each beam irradiated along an optical axis that penetrates through a human body.　A glucose amount estimation method according to the present invention comprises: a step for irradiate a measurement site in a human body with a first beam, a second beam and a third beam that have different wavelengths from one another and receiving the first beam, the second beam and the third beam that have passed through the measurement site by a light receiving element; and a step for estimating the amount of glucose from the light intensities of the first beam, the second beam and the third beam in accordance with a conversion equation. Furthermore, in the present invention, the conversion equation performs a multi-regression analysis, in which the intensities of a first beam, a second beam and a third beam which have different wavelengths from one another and have passed through a human body and the amount of glucose in collected blood are employed as a single actual measurement data set, a plurality of actual measurement data sets are acquired with respect to different glucose amounts, and the multi-regression analysis is performed on the basis of the plurality of actual measurement data sets.

IPC Classes  ?

• G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters

Abstract

In the present invention, a low-molecular-weight compound 2,2,6,6-tetramtethyl-1-piperidinyloxyl (TEMPO) in the gas state is allowed to act on cells to suppress cell death associated with oxidative stress, thereby protecting tissue from tissue damage during the acute phase of ischemic disease.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 9/08 - Solutions
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/72 - Medicinal preparations characterised by special physical form for smoking or inhaling
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 21/02 - Muscle relaxants, e.g. for tetanus or cramps
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 39/06 - Free radical scavengers or antioxidants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

[Problem] To provide an information processing device and program capable of supporting a diagnosis performed by a doctor, by automatically identifying a lesioned portion from the result of a positron emission tomography (PET) examination. [Solution] One aspect of the present invention provides an information processing device for identifying a lesioned portion on the basis of a positron emission tomography examination. The information processing device is provided with an image acquiring unit, and a lesion identifying unit. The image acquiring unit is configured to be capable of acquiring an image including an anatomical region imaged by a positron emission tomography device. The lesion identifying unit is configured to be capable of identifying a lesioned portion from a part of the image in which positron-emitting radionuclides are accumulated, on the basis of trained data obtained by machine learning.

IPC Classes  ?

• G01T 1/161 - Applications in the field of nuclear medicine, e.g. in vivo counting
• G06T 7/00 - Image analysis

Abstract

Provided is a motor control device with which, by employing a neural network structure, an output signal providing optimal efficiency can be derived directly, through training, and with which efficiency can be improved in real-time. A motor control device 1 controls a motor 6, and is provided with a neural network compensator 11 for deriving an output signal providing optimal efficiency, by inputting an input signal and repeating training by means of forward propagation and backpropagation, wherein the input signal is a motor current, a motor parameter, and torque, for example, and the output signal is a current command value or a current phase command value, and wherein the motor 6 is controlled on the basis of the output signal derived by the neural network compensator 11.

IPC Classes  ?

• H02P 21/14 - Estimation or adaptation of machine parameters, e.g. flux, current or voltage

Abstract

11-acidic glycoprotein (fAGP) is useful for the diagnosis of pancreatic cancer and malignant intraductal papillary mucinous carcinoma (IPMC), found is a novel biomarker for pancreatic cancer or malignant IPMC, particularly, a novel biomarker which is useful for rapidly diagnosing IPMC and improves a proper diagnosis rate of malignant IPMC and assists a conventional image diagnosis, by performing a preoperative diagnosis on whether an intraductal papillary mucinous neoplasm (IPMN) is benign or malignant.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

A blood measurement device (10) comprises: a light emitting unit (11) for emitting a light ray that passes through a site (18) being measured; a light receiving unit (19) for receiving the light ray that has passed through the site (18) being measured; an integrating sphere unit (14) disposed in a light path along which the light ray emitted from the light emitting unit (11) travels to the light receiving unit (19), the integrating sphere unit (14) having a reflective surface (26) formed therein for reflecting the light ray; a light inlet (23) that is an opening provided in the integrating sphere unit (14) and through which the light ray emitted from the light emitting unit (11) enters the inside of the integrating sphere unit (14); and a light outlet (16) that is an opening provided in the integrating sphere unit (14) and through which the light ray reflected by the reflective surface (26) of the integrating sphere unit (14) is emitted from the integrating sphere unit (14) toward the site being measured (18).

IPC Classes  ?

• G01N 33/483 - Physical analysis of biological material
• G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters

Abstract

The present invention addresses the problem of evaluating a neural action of a test substance at a high sensitivity, high quantitativeness particularly in a low concentration region and high reproducibility.　This problem can be solved by: a method that successively comprises (A) a step for culturing cultured nerve cells on the surface of a molded body which is formed of a norbornene-based polymer and at least the surface of which is hydrophilized, (B) a step for bringing the cultured nerve cells into contact with a test substance, (C) a step for fixing the cultured nerve cells, (D) a step for visualizing drebrin clusters of dendritic spines of the cultured nerve cells, and (E) a step for measuring the line density along the dendrites of the drebrin clusters, and determining that the test substance has a neural action when the line density increases or decreases compared with the line density of cultured nerve cells which are not contacted with the test substance; and a kit and a culture container to be used in this method.

IPC Classes  ?

• C12N 5/0793 - Neurons
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12Q 1/06 - Quantitative determination
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The present invention addresses the problem of providing a fiber sheet with which deterioration due to the oxidation action of a photocatalyst can be suppressed. Said problem is solved by a photocatalyst-supported copper fiber sheet which comprises: a copper fiber sheet; and a photocatalyst layer laminated on the copper fiber sheet.

IPC Classes  ?

• B01J 35/06 - Fabrics or filaments
• B01J 35/02 - Solids
• B32B 15/08 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
• B32B 15/14 - Layered products essentially comprising metal next to a fibrous or filamentary layer

Abstract

Provided is a polymer composite material or the like containing nanocellulose pieces that can be dispersed in a molten polymer. The polymer composite material contains: a matrix thermoplastic resin that serves as a base material; and flake-like nanocellulose pieces including cellulose nanofibers or cellulose nanocrystals obtained by binding, through covalent bonds or hydrogen bonds, molecules of a thermoplastic resin that is compatible with said matrix thermoplastic resin. The nanocellulose pieces are dispersed in the matrix thermoplastic resin.

IPC Classes  ?

• C08J 3/20 - Compounding polymers with additives, e.g. colouring
• C08L 1/02 - CelluloseModified cellulose
• C08L 23/02 - Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bondCompositions of derivatives of such polymers not modified by chemical after-treatment
• C08L 23/12 - Polypropene
• C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
• C08L 101/00 - Compositions of unspecified macromolecular compounds

Abstract

In the present invention, a promoter on an AAV vector is changed to an Iba1 promoter, and a complementary sequence (miR-9T) of miR-9 and a complementary sequence (miR-129T) of miR-129 are combined. Since it is clearly demonstrated that using this vector makes it possible to express an exogenous gene effectively and specifically on microglia, an AAV vector is found which can express an exogenous gene effectively and specifically on microglia of the central nervous system.

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/12 - Genes encoding animal proteins

Abstract

As therapy using the overexpression of endogenous genes becomes more and more important, there has been required, as a novel gene therapy tool, a small-sized system by which a potent gene can be activated and cloned into a viral vector. The present invention provides a system by which an endogenous gene can be overexpressed. More specifically, provided is a modified SunTag system by which a transcription-associated factor or a chromatin-associated factor and a demethylase are both introduced into a target gene with the use of dCas9-SunTag. According to this system, gene expression can be significantly activated compared to the introduction of the transcription-associated factor or the chromatin-associated factor alone or the demethylase alone. The introduction of the combination of a transcription-associated factor or a chromatin-associated factor with a demethylase using dCas9-SunTag can promote the expression of genes over a wide range, which makes this system applicable to broader targets.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/13 - Immunoglobulins
• C12N 15/53 - Oxidoreductases (1)
• C12N 15/54 - Transferases (2)
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

An imaging device 1 comprises: a variable focus lens 10; and an imaging sensor 15 that outputs a signal corresponding to light. The imaging sensor 15 includes: a photoelectric conversion unit PD that converts light to an electric charge; electric charge reading regions R1-R4; transfer control electrodes E1-E4; a gate control circuit 26 that sequentially applies control signals TG1-TG4 to the transfer control electrodes E1-E4 corresponding to the position of a focus P of the variable focus lens 10; and a reading circuit 27 that outputs a signal corresponding to an electric charge amount transferred to the electric charge reading regions R1-R4. The gate control circuit 26 repeats an operation of respectively outputting the control signals TG1-TG4 when the position of the focus P is in focus ranges BF1-BF4 within a frame period.

IPC Classes  ?

• G03B 15/00 - Special procedures for taking photographsApparatus therefor
• G02B 7/28 - Systems for automatic generation of focusing signals
• G03B 13/34 - Power focusing
• G03B 7/091 - Digital circuits
• H04N 5/225 - Television cameras
• H04N 5/369 - SSIS architecture; Circuitry associated therewith

Abstract

The present invention addresses the problem of providing a therapeutic agent for carcinomatous peritonitis. The present invention provides a therapeutic agent that is for carcinomatous peritonitis and that contains an antibody that recognizes a transferrin receptor.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 15/13 - Immunoglobulins
• C12P 21/08 - Monoclonal antibodies

Abstract

Provided is an electrode for a redox flow battery, the electrode being configured from a plate-form carbon electrode material in which uniform communication macro holes are formed in three-dimensional mesh form and there is no contact interface between carbon particles, and moreover being such that the average macro hole diameter of the carbon electrode material is within the range of 6-35 µm, the surface interval of a graphite crystallite (002) surface in the carbon electrode material is within the range of 0.33-0.40 nm, and the c-axis-direction crystallite size of the graphite crystallite is within the range of 0.9-8.5 nm.

IPC Classes  ?

• H01M 4/88 - Processes of manufacture
• H01M 4/96 - Carbon-based electrodes
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells

Abstract

22, R1is a hydrogen atom, an alkoxy group having 1 to 4 carbon atoms, or an alkyl group having 1 to 10 carbon atoms which may be branched, R2is a hydrogen atom, halogen, an alkyl group having 1 to 10 carbon atoms which may be branched, a cycloalkyl group having 3 to 8 carbon atoms, or an alkoxy group having 1 to 4 carbon atoms, R3is a hydrogen atom, an alkyl group having 1 to 10 carbon atoms which may be branched, or an alkoxy group having 1 to 4 carbon atoms, and R4is a cycloalkyl group having 3 to 8 carbon atoms, a pyridyl group which may have a substituent, a pyrimidyl group which may have a substituent, a pyrazyl group which may have a substituent, a piperidyl group which may have a substituent, a piperazyl group which may have a substituent, a group represented by R41, a group represented by R42, a group represented by R43, or a group represented by R44.

IPC Classes  ?

• A61P 33/00 - Antiparasitic agents
• C07C 233/61 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
• C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 213/81 - AmidesImides
• C07D 213/82 - AmidesImides in position 3
• C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
• C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
• C07D 239/42 - One nitrogen atom
• C07D 241/20 - Nitrogen atoms
• C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim

Abstract

The purpose of the present invention is to provide a volumetric display that is capable of rapid image presentation. The focal length of a resonance-type liquid lens 2 is periodically adjusted using resonance of a liquid. An image projection unit 1 projects an image toward the viewpoint position of a user via the resonance-type liquid lens 2. Furthermore, the image projection unit 1 projects an image toward the viewpoint position within a time that is less than 1/10 the cycle of fluctuation of the focal length. The image projection unit 1 is configured from an LED and a DMD, for example.

IPC Classes  ?

• G02B 30/54 - Optical systems or apparatus for producing three-dimensional [3D] effects, e.g. stereoscopic images the image being built up from image elements distributed over a 3D volume, e.g. voxels the 3D volume being generated by moving a 2D surface, e.g. by vibrating or rotating the 2D surface
• G02B 3/14 - Fluid-filled or evacuated lenses of variable focal length
• G02B 27/02 - Viewing or reading apparatus
• H04N 13/322 - Image reproducers for viewing without the aid of special glasses, i.e. using autostereoscopic displays using varifocal lenses or mirrors
• H04N 13/344 - Displays for viewing with the aid of special glasses or head-mounted displays [HMD] with head-mounted left-right displays
• H04N 13/365 - Image reproducers using digital micromirror devices [DMD]
• H04N 13/393 - Volumetric displays, i.e. systems where the image is built up from picture elements distributed through a volume the volume being generated by a moving, e.g. vibrating or rotating, surface
• H04N 13/398 - Synchronisation thereofControl thereof

Abstract

A guide mechanism for a conveyance cart according to the present invention, said mechanism comprising a permanent magnet, two electromagnet units, and a holding member. Each electromagnet unit comprises: a core including a first iron core section, a second iron core section, and a third iron core section; and coil sections wound around the respective iron core sections so as to change the magnetic flux density acting between each iron core section and a guide rail when electric power is supplied. The first iron core section is positioned below the guide rail and attracts the guide rail from below. The second iron core section is positioned at one end side in the width direction of the conveyance cart, and attracts the guide rail from the one end side in the width direction of the conveyance cart. The third iron core section is disposed at a predetermined spacing from the second iron core section in the width direction of the conveyance cart, and attracts the guide rail in a direction opposite to the direction of attraction by the second iron core section. Furthermore, the holding member holds the two electromagnet units and the permanent magnet in a state where the permanent magnet is sandwiched by the two electromagnet units, and sets the width direction of the conveyance cart in a longitudinal direction and is axially supported by a support member fixed to a link member of the conveyance cart.

IPC Classes  ?

• B61B 13/08 - Sliding or levitation systems
• B65G 54/02 - Non-mechanical conveyors not otherwise provided for electrostatic, electric, or magnetic
• B60L 13/04 - Magnetic suspension or levitation for vehicles

Abstract

The present invention addresses the problem of developing a reagent and a compound having a long phosphorescence lifetime for imaging of a low-oxygen cell or tissue, or measurement or quantification of the oxygen concentration in the low-oxygen cell or tissue. The present invention provides an oxygen concentration measurement reagent which contains a compound represented by general formula (I) or (II). (In the formulae, each of R1and R2independently represents a hydrogen atom or a hydrocarbon group having from 1 to 6 carbon atoms; and X- represents a counter anion.)

IPC Classes  ?

• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 491/16 - Peri-condensed systems
• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods
• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
• A61K 49/10 - Organic compounds
• G01N 33/483 - Physical analysis of biological material

Abstract

To provide a physiologically active agent for oral administration that contains a modified konjac flour as an active ingredient, said modified konjac flour comprising a water-soluble dietary fiber and an insoluble dietary fiber in a well-balanced manner, having good handling properties and high storage stability, being easily usable routinely and having a vegetable-like physiological activity. For this purpose, a modified konjac flour comprising 8-50 mass% of a water-soluble dietary fiber and 92-50 mass% of an insoluble dietary fiber is used as an active ingredient of a physiologically active agent for oral administration. The physiologically active agent for oral administration according to the present invention can be used as a blood glucose level elevation inhibitor.

IPC Classes  ?

• A61P 1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 9/14 - Particulate form, e.g. powders
• A61K 36/888 - Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
• A61K 135/00 - Containing or obtained from stems, stalks, branches, twigs or shoots
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
• A61K 31/736 - Glucomannans or galactomannans, e.g locust bean gum, guar gum

Abstract

AABBB) of the light-receiving surface side. A reduced metal fine particle group (average particle diameter 20nm) was made to self-aggregate on a transparent polyester resin film, was halfway embedded, and was fixed. The resulting base material was repeatedly submerged in an electroless metal plating liquid, and metal particles were deposited on metal fine particle bodies. 10 microliters of a protein solution were dripped onto this nanostructure substrate and crystallized using a hanging drop vapor diffusion method.

IPC Classes  ?

• C07K 1/04 - General processes for the preparation of peptides on carriers
• C07K 1/14 - ExtractionSeparationPurification

Abstract

2y33; and y is an integer between 0 and 5.)

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

The present invention addresses the problem of establishing a method for the direct, rapid and simple high-throughput evaluation of an NMDA receptor inhibition activity. An NMDA receptor inhibition activity can be evaluated with high throughput by a method comprising the following steps in this order: (A) bringing a substance of interest into contact with cultured neurons; (B) bringing the cultured neurons into contact with a glutamate solution; (C) immobilizing the cultured neurons; (D) visualizing drebrin clusters of dendritic spines of the cultured neurons; and (E) measuring the line density along the dendrites of the drebrin clusters, and determining that the substance of interest has an NMDA receptor inhibition activity when the line density is higher than the line density of the cultured neurons that are not contacted with the substance of interest.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 33/15 - Medicinal preparations
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

This object surface processing method comprises: (a) a resin layer forming step of forming a resin layer containing a photosensitive resin on a substrate; (b) a primary irradiation step of irradiating light onto the resin layer from the surface on the side of the substrate which is opposite the side on which the resin layer has been formed; (c) an object disposition step of disposing, on the light-irradiated resin layer, an object having a non-flat surface, and (d) a secondary irradiation step of further irradiating light onto the resin layer from the surface on the side of the substrate which is opposite the side on which the resin layer has been formed, wherein the primary irradiation step is carried out under conditions wherein a portion of the resin layer is not cured, and the object disposition step is carried out in such a manner that the non-flat surface of the object faces the resin layer.

IPC Classes  ?

• B29C 59/16 - Surface shaping, e.g. embossingApparatus therefor by wave energy or particle radiation
• A61L 27/38 - Animal cells
• A61L 27/40 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 27/56 - Porous or cellular materials
• B32B 3/30 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layerLayered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a layer with cavities or internal voids characterised by a layer formed with recesses or projections, e.g. grooved, ribbed
• B32B 5/18 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by features of a layer containing foamed or specifically porous material
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus

Abstract

1λ12λ11λ22λ2ggg, and the number n of particles.

IPC Classes  ?

• G01N 15/02 - Investigating particle size or size distribution
• G01N 15/06 - Investigating concentration of particle suspensions

Abstract

In the present invention, a coating layer containing a fluoropolymer having a sulfonic acid group is laminated on at least one surface of a substrate layer containing a modified graphene oxide modified with a vinyl group-containing sulfonic acid. A first coating layer and a second coating layer may respectively be laminated on the two surfaces of the substrate layer. The sulfur content in the modified graphene oxide measured by element analysis may be 0.5-10 Atom%. The vinyl group-containing sulfonic acid may be vinylsulfonic acid or a metal salt thereof. By using the obtained laminate as a proton conductive electrolysis membrane in a solid fuel cell, the cell can be driven at room temperature and the proton conductivity and the output stability can be improved.

IPC Classes  ?

• B32B 9/00 - Layered products essentially comprising a particular substance not covered by groups
• B32B 27/30 - Layered products essentially comprising synthetic resin comprising vinyl resinLayered products essentially comprising synthetic resin comprising acrylic resin
• H01B 1/06 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances
• H01B 13/00 - Apparatus or processes specially adapted for manufacturing conductors or cables
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 8/1004 - Fuel cells with solid electrolytes characterised by membrane-electrode assemblies [MEA]
• H01M 8/1032 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer having sulfur, e.g. sulfonated-polyethersulfones [S-PES]
• H01M 8/1053 - Polymer electrolyte composites, mixtures or blends consisting of layers of polymers with at least one layer being ionically conductive
• H01M 8/1069 - Polymeric electrolyte materials characterised by the manufacturing processes
• H01M 8/1072 - Polymeric electrolyte materials characterised by the manufacturing processes by chemical reactions, e.g. insitu polymerisation or insitu crosslinking

Abstract

The objective of the present invention is to provide a radiation measuring body and a radiation exposure dose measuring device which can be realized relatively inexpensively using a simple structure, and with which the exposure dose to which the crystalline lens of a subject, for example, is subjected can be measured rapidly and accurately. The radiation measuring body can be realized by forming a transparent dosimeter on a lens in the form of known spectacles, goggles, retrofitted sunglasses and the like, or protective glasses. The radiation exposure dose measuring device consists of a light shielding box in which the radiation measuring body is confined in order to block external light, and a computer. The computer includes a sequence control unit which controls a switch for blocking noise when the radiation measuring body is irradiated with exciting light and an amount of emitted light is measured.

IPC Classes  ?

• G01T 7/00 - Details of radiation-measuring instruments
• G01T 1/02 - Dosimeters
• A61B 6/10 - Safety means specially adapted therefor

Abstract

in vitroin vivoin vivo or ameliorates inflammation. Namely, the anti-S100A8/A9 antibody or an antibody fragment thereof has an effect of blocking the interaction between S100A8/A9 and the receptors thereof and thus can strongly inhibit cancer metastasis or ameliorate inflammation.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C12N 15/13 - Immunoglobulins

Abstract

The present invention addresses the problem of preparing a carbon-based composite for an oxygen reduction catalyst, the carbon-based composite comprising: a nanosheet-like graphene oxide or a reduction product thereof; and carbon quantum dots. The average particle diameter of the carbon quantum dots may be 20 nm or less. The nanosheet-like graphene oxide or the reduction product thereof, and the carbon quantum dots may be complexed in a uniformly mixed state. The carbon quantum dots may contain nitrogen atoms. The weight ratio of the nanosheet-like graphene oxide or the reduction product thereof to the carbon quantum dots may be 90/10 to 10/90 (the former/the latter). The carbon-based composite and a conductive aid may be combined to prepare a composite for a battery cathode catalyst layer. The conductive aid may be Ketjenblack. The carbon-based composite can be prepared simply and inexpensively, does not contain platinum, and can exhibit excellent oxygen reduction electrode characteristics.

IPC Classes  ?

• B01J 21/18 - Carbon
• B01J 35/02 - Solids
• B01J 37/10 - Heat treatment in the presence of water, e.g. steam
• B01J 37/16 - Reducing
• B01J 37/34 - Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves
• C01B 32/15 - Nanosized carbon materials
• C01B 32/194 - After-treatment
• C01B 32/198 - Graphene oxide
• H01M 4/88 - Processes of manufacture
• H01M 4/90 - Selection of catalytic material
• H01M 4/96 - Carbon-based electrodes
• H01M 8/10 - Fuel cells with solid electrolytes

Abstract

Provided are an objective pain sensation measurement device and an objective pain sensation measurement method which are capable of detecting pain sensation with high accuracy, which is caused by a certain physical stimulus to a subject, without being influenced by the subjectivity of the subject, and of measuring a degree of the pain sensation. Before the physical stimulus is applied to the subject, a moving average value of skin conductance is stored in advance in a skin conductance initial value memory as a skin conductance initial value. In addition, a change rate of the skin conductance is calculated on the basis of the skin conductance initial value. The pain sensation based on the physical stimulus can be specifically detected and objective measurement of the pain sensation can be implemented by measuring the presence or absence of pain sensation, or the degree of the pain sensation by using the change rate of the skin conductance.

IPC Classes  ?

• A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

The purpose of the present invention is to provide a method for predicting the efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy and a method for evaluating the grade of a cancer that are based on a novel biomarker. This method for predicting the efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy on a subject includes a step for measuring the LAT1 expression level in a sample collected from the cancerous tissue of the subject, and a step for predicting the efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy on the subject on the basis of the LAT1 expression level. The method for evaluating the grade of a cancer in a subject includes a step for using anti-LAT1 antibodies and anti-PD-L1 antibodies to stain a sample collected from the cancerous tissue of the subject, and a step for evaluating the grade of the cancer in the subject on the basis of the presence or absence of LAT1-positive and PD-L1-positive sites.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

[Problem] To provide a polymer/nanoparticle composite hydrogel having outstanding mechanical properties and elongation properties, and which can be produced with general-purpose materials which can be obtained easily in industrial terms. [Solution] A self-supporting hydrogel containing a silicate (A), a polyalkylene glycol (B) and a silicate dispersant (C), the hydrogel being characterized in that the polyalkylene glycol (B) has a weight-average molecular weight, number-average molecular weight or viscosity-average molecular weight of 500,000 to 20,000,000, and with respect to 100% by mass of the hydrogel, the polyalkylene glycol (B) accounts for more than 2% by mass but not more than 20% by mass. A method for producing the self-supporting hydrogel is also provided.

IPC Classes  ?

• C08L 71/02 - Polyalkylene oxides
• B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
• C08J 3/075 - Macromolecular gels
• C08K 3/34 - Silicon-containing compounds
• C08K 5/52 - Phosphorus bound to oxygen bound to oxygen only

Abstract

The purpose of the present invention is to provide a method for conveniently and industrially producing at low cost, a compound having a polyene skeleton and containing hydrogen and fluorine and/or chlorine. Provided is a method for producing a halogenated diene represented by formula (1), A1A2C=CA3-CA4=CA5A6 [in the formula, A1, A2, A5, and A6 independently represent hydrogen, fluorine or chlorine, a C1-3 (perfluoro) alkyl group or (perfluoro) alkenyl group, A3 and A4 independently represent hydrogen, fluorine or chlorine, at least one among A1-A6 represents hydrogen, and at least one among A1-A6 represents fluorine or chlorine], the method comprising a step for subjecting identical or different halogenated olefins represented by formula (2), A7A8C=CA9X [in the formula, A7 and A8 independently represent hydrogen, fluorine or chlorine, a C1-3 (perfluoro) alkyl group or (perfluoro) alkenyl group, A9 independently represents hydrogen, fluorine or chlorine, and X represents bromine or iodine], to a coupling reaction in the presence of a zero-valent metal.

IPC Classes  ?

• C07C 17/269 - Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions of only halogenated hydrocarbons
• C07C 21/20 - Halogenated butadienes
• C07B 61/00 - Other general methods

Abstract

A method for detecting a target molecule, wherein: the method includes a step for forming a complex of a target molecule, a capture oligonucleotide, an oligonucleotide primer, and a single-stranded circular DNA, a step for conducting a nucleic acid amplification reaction based on complex formation by rolling circle amplification, and a step for detecting the amplified nucleic acid; the single-stranded circular DNA includes a first region and a second region linked to the 3' side of the first region, and preferably also a sequence complementary to the detection-reagent-binding sequence; the primer includes a first aptamer sequence that binds to the target molecule and a sequence that is complementary to the first region of the single-stranded circular DNA and is linked to the 3' side of the first aptamer sequence; and the capture oligonucleotide includes a sequence complementary to the second region of the single-stranded circular DNA and a second aptamer sequence that binds to the target molecule and is linked to the 3' side of the sequence.

IPC Classes  ?

• C12Q 1/6844 - Nucleic acid amplification reactions
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

Provided are a production method for a conditional knockout animal and associated techniques (e.g. an effective production method for a floxed animal). An animal having a pair of recombinase recognition sequences on a chromosome, i.e. a floxed animal, is produced by introducing a recombinase recognition sequence such as loxP at each end of a target site on a chromosome at different times.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

Provided are a carbon catalyst with improved catalytic activity and an electrode and battery containing the same. A carbon catalyst according to an embodiment of the present invention contains metal and phosphorus atoms, with the proportion of phosphorus atom concentration (atomic %), which has a peak top in the range of 132.5 ± 0.3 eV obtained by peak separation of the phosphorus atom P2p peaks and shows a peak with a full width at half maximum of 2.0 ± 0.5 eV, to carbon atom concentration (atomic %) being 0.0005 or greater in x-ray photoelectron spectroscopic measurements.

IPC Classes  ?

• B01J 27/185 - PhosphorusCompounds thereof with iron group metals or platinum group metals
• H01M 4/90 - Selection of catalytic material

Abstract

Provided are a novel nucleoside derivative or salt thereof, polynucleotide synthesis reagent, polynucleotide production method, polynucleotide, and binding nucleic acid molecule production method. This nucleoside derivative or salt thereof is characterized in being represented by chemical formula (1). In chemical formula (1): Su is an atom group with a sugar backbone in the nucleoside residue or an atom group with a sugar phosphate backbone in the nucleotide residue, and may or may not have a protecting group; each of L1 and L2 independently is a straight or branched saturated or unsaturated C2-10 hydrocarbon group; X1 is an imino group (-NR1-), ether group (-O-) or thioether group (-S-); and R1 is a hydrogen atom or straight or branched saturated or unsaturated C2-10 hydrocarbon group.

IPC Classes  ?

• C07H 19/073 - Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
• C12N 15/09 - Recombinant DNA-technology

Abstract

This biaxial stretching device has: X-direction bars and Y-direction bars which are arranged in a grid-like arrangement such that the central part of a grid serves as a place where a square-shaped object to be stretched is disposed; a plurality of moving chucks which are movably mounted in the longitudinal directions of the X-direction and Y-direction bars and which are capable of gripping outer edges of the object to be stretched; a first drive means which moves the X-direction and Y-direction bars in a direction orthogonal to the respective longitudinal directions; and a second drive means which moves the moving chucks in the respective longitudinal directions of the X-direction and Y-direction bars.

IPC Classes  ?

• B29C 55/16 - Shaping by stretching, e.g. drawing through a dieApparatus therefor of plates or sheets multiaxial biaxial simultaneously

Abstract

Provided is a method for efficiently producing peripheral nerve cells at high purity from undifferentiated cells. This method for producing peripheral nerve cells is for producing peripheral nerve cells from undifferentiated cells with the potency to differentiate into peripheral nerve cells, the method comprising the following steps: (a) culturing undifferentiated cells with the potency to differentiate into peripheral nerve cells and inducing differentiation into nerve progenitor cells without detaching grown colonies from a culture vessel; and (b) after detaching nerve progenitor cells generated in step (a) from the culture vessel, seeding the cells into the culture vessel at a seeding density of 2×105 to 6×105 cells/cm2 and culturing the cells for 14-42 days.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0793 - Neurons
• C12N 5/0797 - Stem cellsProgenitor cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

Provided are a conductive rubber composition for measuring bio-signals, a conductive member for measuring bio-signals, and clothing for measuring bio-signals, which feel good when contacting the skin and exhibit good bio-signal receivability, even when applied to skin having a low moisture content. Provided are: a conductive rubber composition for measuring bio-signals, the conductive rubber composition containing a rubber component having a crosslinked structure, conductive metal particles, an adhesive, a polar solvent, and at least one selected from the group consisting of synthetic rubbers and elastomers; and applications of the conductive rubber composition.

IPC Classes  ?

• A61B 5/0408 - Electrodes specially adapted therefor
• A61B 5/0402 - Electrocardiography, i.e. ECG
• A61B 5/0478 - Electrodes specially adapted therefor
• C08K 3/08 - Metals
• C08L 21/00 - Compositions of unspecified rubbers
• C08L 33/08 - Homopolymers or copolymers of acrylic acid esters
• C08L 75/04 - Polyurethanes
• H01B 1/22 - Conductive material dispersed in non-conductive organic material the conductive material comprising metals or alloys

Abstract

An X-ray CT device is provided with a processing unit for processing data obtained by detecting X-rays radiated from an X-ray light source of a light source unit and transmitted through a measurement object, the processing unit finding an absorption coefficient µ(k) for each energy region k of each calibration tool from data obtained by measuring two or more types of calibration tools in a plurality of energy regions, calculates calibration coefficients F(k), G(k) for the energy regions k on the basis of equation (3) from the absorption coefficient found for each calibration tool, finds an absorption coefficient µ(k) for each energy region k of a measurement object from data obtained by measuring a measurement object in each of a plurality of energy regions, and calculates the electron density ρe and the effective atomic number Z of the measurement object on the basis of equation (4) from the calibration coefficients F(k), G(k) for the energy regions k and the absorption coefficients µ(k) for the energy regions k of the measurement object.

IPC Classes  ?

• A61B 6/03 - Computed tomography [CT]
• G01N 23/04 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and forming images of the material
• G01N 23/087 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and measuring the absorption the radiation being X-rays using polyenergetic X-rays

Abstract

Provided are a novel nucleoside derivative or a salt thereof, a reagent for synthesizing a polynucleotide, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. This nucleoside derivative or a salt thereof is characterized by being represented by chemical formula (1). [Chem. 1] In chemical formula (1), Su represents an atomic group having a sugar backbone in the nucleoside residue or an atomic group having a sugar phosphate backbone in the nucleotide residue, which may or may not have a protecting group, L1 and L2 each independently represent a linear or branched saturated or unsaturated hydrocarbon group having 2-10 carbon atoms, X1 and X2 each independently represent an imino group (-NR1-), an ether group (-O-), or a thioether group (-S-), and R1 represents a hydrogen atom or a linear or branched saturated or unsaturated hydrocarbon group having 2-10 carbon atoms.

IPC Classes  ?

• C07H 19/073 - Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
• C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

Abstract

Provided is a novel molecule which can be used to detect sIgA. This secretory immunoglobulin A (sIgA)-binding nucleic acid is characterized by being a nucleic acid molecule having a dissociation constant for sIgA of 37.7 nM or less. For example, the nucleic acid preferably includes a polynucleotide having a base sequence of any of SEQ ID NO. 1-12, or a polynucleotide having a partial sequence thereof. The nucleic acid molecule according to the present invention can be used to detect sIgA in saliva.

IPC Classes  ?

• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

Provided are a novel nucleoside derivative or a salt thereof, a reagent for synthesizing a polynucleotide, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. This nucleoside derivative or a salt thereof is characterized by being represented by chemical formula (1). In chemical formula (1), Su represents an atomic group having a sugar backbone in the nucleoside residue or an atomic group having a sugar phosphate backbone in the nucleotide residue, and the atomic group may or may not have a protecting group, L1 and L2 each independently represent a linear or branched saturated or unsaturated hydrocarbon group having 2-10 carbon atoms, X1 and X2 each independently represent an imino group (-NR1-), an ether group (-O-), or a thioether group (-S-), and R1 represents a hydrogen atom or a linear or branched saturated or unsaturated hydrocarbon group having 2-10 carbon atoms.

IPC Classes  ?

• C07H 19/073 - Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
• C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

Abstract

Provided are a novel nucleoside derivative or a salt thereof, a reagent for synthesizing a polynucleotide, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. This nucleoside derivative or a salt thereof is characterized by being represented by chemical formula (1). In chemical formula (1), Su represents an atomic group having a sugar backbone in the nucleoside residue or an atomic group having a sugar phosphate backbone in the nucleotide residue, which may or may not have a protecting group, L1 and L2 each independently represent a linear or branched saturated or unsaturated hydrocarbon group having 2-10 carbon atoms, X1 and X2 each independently represent an imino group (-NR1-), an ether group (-O-), or a thioether group (-S-), and R1 represents a hydrogen atom or a linear or branched saturated or unsaturated hydrocarbon group having 2-10 carbon atoms.

IPC Classes  ?

• C07H 19/20 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

Abstract

Provided are a novel nucleoside derivative or a salt thereof, a reagent for synthesizing a polynucleotide, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. This nucleoside derivative or a salt thereof is characterized by being represented by chemical formula (1). [Chem. 1] In chemical formula (1), Su represents an atomic group having a sugar backbone in the nucleoside residue or an atomic group having a sugar phosphate backbone in the nucleotide residue, which may or may not have a protecting group, L1 and L2 each independently represent a linear or branched saturated or unsaturated hydrocarbon group having 2-10 carbon atoms, X1 and X2 each independently represent an imino group (-NR1-), an ether group (-O-), or a thioether group (-S-), and R1 represents a hydrogen atom or a linear or branched saturated or unsaturated hydrocarbon group having 2-10 carbon atoms.

IPC Classes  ?

• C07H 19/20 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

Abstract

Provided is a simple method for producing perfluoroalkyl compounds that serve as important intermediates for organic electronic materials, pharmaceuticals, agricultural chemicals, polymer functional materials, etc., the method involving the use of monohydroperfluoroalkanes as a starting material. A base is caused to act on a monohydroperfluoroalkane and a reaction with a carbonyl compound is furthermore carried out, whereby an alcohol having a perfluoroalkyl group is produced. For example, potassium hydroxide is caused to act on trifluoromethane and a reaction with a carbonyl compound is carried out, whereby an alcohol having a trifluoromethyl group is produced.

IPC Classes  ?

• C07C 29/38 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy groups, e.g. O-metal by reaction with aldehydes or ketones
• C07C 31/125 - Monohydroxylic acyclic alcohols containing five to twenty-two carbon atoms
• C07C 33/46 - Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic part
• C07C 35/48 - Halogenated derivatives
• C07C 43/23 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
• C07C 209/68 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
• C07C 211/48 - N-alkylated amines
• C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
• C07C 233/15 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring

Abstract

A method for detecting a gene mutation, comprising the steps of: hybridizing a target polynucleotide that contains a first region and a second region adjacent to the 3' side of the first region and having a mutation with single-stranded cyclic DNA and a primer; carrying out a nucleic acid amplification reaction based on the formation of a complex of the target polynucleotide, the primer and the single-stranded cyclic DNA by rolling circle amplification; and detecting the amplified nucleic acid with a detection reagent. In the method, the single-stranded cyclic DNA contains a sequence complementary to the first region in the target polynucleotide, a primer-binding sequence adjacent to the 5' side of this sequence, and preferably a sequence complementary to a detection reagent-binding sequence; and the oligonucleotide primer contains a region having a sequence complementary to the second region in the target polynucleotide and a region adjacent to the 3' side of the this sequence and having a sequence complementary to the primer-binding sequence in the single-stranded cyclic DNA.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/09 - Recombinant DNA-technology

Abstract

Provided are a carbon catalyst, a battery electrode, and a battery which exhibit superior catalytic performance. A carbon catalyst according to an embodiment of the present invention includes two types of transition metal and has a carbon structure wherein the surface interval d002 is 0.374 nm or greater, said surface interval being found from the Bragg angle for one, which is the diffraction peak fbroad, of three diffraction peaks, fbroad, fmiddle, and fnarrow, obtained by separating diffraction peaks in the vicinity of a diffraction angle (2θ) of 26° in an x-ray diffraction pattern for powder x-ray diffraction using a CuKα radiation.

IPC Classes  ?

• B01J 23/80 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with zinc, cadmium or mercury
• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,
• H01M 4/90 - Selection of catalytic material
• H01M 4/96 - Carbon-based electrodes
• H01M 8/10 - Fuel cells with solid electrolytes

Abstract

[Problem] To provide a scope distal end portion cleaning tool which is compact and easy to handle, which can rapidly remove waste solution in a chamber, and which can uniformly clean a distal end portion of a scope. [Solution] A scope distal end portion cleaning tool 100 is provided with a water storage tube 10. The water storage tube 10 includes a gas/liquid inflow passage 11 into which air and a cleaning solution flow, and a water storage portion 12 for storing the cleaning solution that has flowed in through the gas/liquid inflow passage 11. The configuration is such that the cleaning solution in the water storage portion 12 is introduced, together with air that has flowed in through the gas/liquid inflow passage 11, into a cleaning chamber 20 for cleaning the scope distal end portion.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• B08B 3/02 - Cleaning by the force of jets or sprays
• B08B 3/04 - Cleaning involving contact with liquid
• G02B 23/24 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes

Abstract

A DNA methylation editing kit including: (1) a fused protein of inactivated CRISPR-associated endonuclease Cas9 (dCas9) having no nuclease activity and a tag peptide array in which a plurality of tag peptides are linked by linkers, or RNA or DNA encoding the fused protein; (2) a fused protein of a tag peptide binding site and a methylase or demethylase, or RNA or DNA encoding the fused protein; and (3) guide RNA (gRNA) that includes a sequence complementary to a DNA sequence within 1 kb of a desired site of methylation or demethylation, or DNA expressing the gRNA.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 9/10 - Transferases (2.)

Abstract

A phenacene compound represented by general formula (1). In general formula (1), R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 each independently represent a hydrogen atom or a group represented by general formula (2), and any one of R3, R5, and R6 is a group represented by general formula (2). R9 and R10, together with the carbon atoms to which R9 and R10 are bonded, may bond to each other to form a condensed ring. In general formula (2), * indicates the bonding position with a compound represented by general formula (1). X indicates a halogen group, and Y1 represents an aryl group or heteroaryl group.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• C07C 45/67 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by isomerisationPreparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by change of size of the carbon skeleton
• C07C 45/77 - Preparation of chelates of aldehydes or ketones
• C07C 49/784 - Ketones containing a keto group bound to a six-membered aromatic ring polycyclic with all keto groups bound to a non-condensed ring
• C07C 49/92 - Ketonic chelates
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)

Abstract

[Problem] To provide a radiation measuring instrument having good heat resistance and radiation resistance. [Solution] Provided are a charged particle radiation measuring method and a charged particle radiation measuring device employing a scintillator containing a phosphor having SiAlON phosphor as the main component.

IPC Classes  ?

• G01T 1/20 - Measuring radiation intensity with scintillation detectors
• C09K 11/00 - Luminescent, e.g. electroluminescent, chemiluminescent, materials
• C09K 11/64 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing aluminium
• G01T 1/202 - Measuring radiation intensity with scintillation detectors the detector being a crystal

Abstract

The present invention is characterized by comprising: an acid leaching step for obtaining a leach liquid by causing leaching of, by means of an acid, a metal mixture at least containing vanadium and at least one type of a divalent or trivalent metal selected from nickel, cobalt, manganese, palladium, platinum, copper, and zinc; a complex generation step for adding an ammoniacal alkaline aqueous solution to the leach liquid for adjusting the pH to 10-12 and generating, in the alkaline aqueous solution, an ammine complex of a divalent or trivalent metal ion and an anion complex of a tetravalent and/or pentavalent vanadium ion; a divalent or trivalent metal recovery step for adding a carrier having a carboxyl group to the alkaline aqueous solution in which the ammine complex and the anion complex are generated, causing the divalent or trivalent metal ion in the ammine complex to be selectively adsorbed by the carrier, and recovering the divalent or trivalent metal ion; and a vanadium recovery step for recovering vanadium from the anion complex contained in the alkaline aqueous solution after the divalent or trivalent metal ion is recovered.

IPC Classes  ?

• C22B 34/22 - Obtaining vanadium
• C22B 3/24 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means by adsorption on solid substances, e.g. by extraction with solid resins
• C22B 3/44 - Treatment or purification of solutions, e.g. obtained by leaching by chemical processes

Abstract

Provided are a hydrogen storage carbon material having a carbon structure suitable for hydrogen storage, and a method for producing the hydrogen storage carbon material. This hydrogen storage carbon material has a carbon structure in which the proportion of the ultra-micro pore volume to the micro pore volume is 60% or more, and, in 1H-NMR measurement, stored hydrogen has a second peak at a position corresponding to a chemical shift of -2 ppm to -20 ppm with respect to a first peak attributed to gaseous hydrogen.

IPC Classes  ?

• B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• C01B 3/00 - HydrogenGaseous mixtures containing hydrogenSeparation of hydrogen from mixtures containing itPurification of hydrogen
• G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance

Abstract

The problem addressed by the present invention is to provide a method and device which are capable, in response to subject diversity, of evaluating the fluidity of blood, and of clearly detecting the state of a subject with blood vessels and blood flow in various states. The present invention provides a blood fluidity evaluation method, comprising steps of: carrying out a plurality of iterations of a pressing cycle of pressing a pressing member with a force of a primary pressure upon a subject site of a subject and causing blood in the subject site to flow outward into the surrounding part of the subject site, reducing the force which presses upon the pressing member to a secondary pressure, releasing the force which presses the pressing member, and raising the pressing force which presses the pressing member to the primary pressure; and in between the iterations thereof, measuring a change over time of the volume of blood in the subject site, using light scattering analysis. The secondary pressure has at least two different values over the course of the plurality of iterations of the pressing cycle.

IPC Classes  ?

• A61B 5/026 - Measuring blood flow
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow

Abstract

Provided is an RNA detection kit including: (i) a single-stranded circular DNA template that includes a sequence of 10-30 bases complementary to a first site of a target RNA, a primer binding sequence of 7-8 bases adjacent to the 5’ side of this sequence, and a sequence complementary to a detection reagent binding sequence such as a G-quadruplex-forming sequence; (ii) an oligonucleotide primer that includes a sequence of 8-15 bases complementary to a second site adjacent to the 3’ side of the first site of the target RNA and a sequence of 7-8 bases complementary to a single-stranded circular DNA template primer binding sequence adjacent to the 3’ side of this sequence; and (iii) a detection reagent such as a G-quadruplex binding reagent.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Disclosed is a modified polymerase that comprises an amino acid sequence having prescribed mutations in the amino acid sequence represented by SEQ ID NO:2 of Sequence Listing. According to the present invention, a polymerase having an LNA chain extension activity and a polymerase having a reverse transcription activity are provided.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

The present invention applies carbon nanotubes to catalyst particles, thereby providing catalyst particles which are usable in fluidized bed reactions, have high catalytic activity, and are easy to handle. The catalyst particles are carbon-nanotube-coated catalyst particles which each comprise a support particle and a coating layer disposed on the surface of the support particle, wherein the support particles are flowable in fluidized beds and the coating layer comprises carbon nanotubes which have metal nanoparticles supported thereon and/or which have been doped with nitrogen or boron. The carbon-nanotube-coated catalyst particles are flowable in fluidized bed reactions.

IPC Classes  ?

• B01J 23/755 - Nickel
• B01J 35/02 - Solids
• B01J 35/06 - Fabrics or filaments
• B01J 37/02 - Impregnation, coating or precipitation
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C01B 31/02 - Preparation of carbon; Purification

Abstract

Provided is a method for joining metal members in which joining is possible at a comparatively low temperature and deformation during joining can be suppressed. The method has a step in which metal sheets (21), in which an organic acid-salt film of a metal is formed on the surface of the sheets (21), are interposed at the joining surfaces so that a plurality of metal members (1, 2, 3, 4, 5, 6) are joined; aluminum or an aluminum alloy being used for the metal members (1, 2, 3, 4, 5, 6), and sheets (21) of any of zinc, copper, or magnesium being used for the metal sheets (21).

IPC Classes  ?

• B23K 20/16 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating with interposition of special material to facilitate connection of the parts, e.g. material for absorbing or producing gas
• B23K 20/00 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating

Abstract

Provided is a carbon catalyst, electrode and battery exhibiting excellent activity. A carbon catalyst according to one embodiment of the present invention has a carbon structure wherein the area ratios of three peaks fbroad, fmiddle, and fnarrow obtained by separating a peak in the vicinity of a diffraction angle of 26° in an X-ray diffraction pattern obtained by powder X-ray diffraction satisfy the conditions (a)-(c): (a) fbroad: 75-96%, inclusive; (b) fmiddle: 3.2-15%, inclusive; and (c) fnarrow: 0.4-15%, inclusive.

IPC Classes  ?

• B01J 21/18 - Carbon
• B01J 37/08 - Heat treatment
• C01B 31/02 - Preparation of carbon; Purification
• H01M 4/90 - Selection of catalytic material
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 12/06 - Hybrid cellsManufacture thereof composed of a half-cell of the fuel-cell type and of a half-cell of the primary-cell type with one metallic and one gaseous electrode
• H01M 12/08 - Hybrid cellsManufacture thereof composed of a half-cell of a fuel-cell type and a half-cell of the secondary-cell type

Abstract

Provided is a carbon material that is compact and exhibits excellent hydrogen storage performance. A carbon material according to one embodiment of the present invention has a specific surface area of 200 m2/g or less and exhibits a hydrogen storage performance of 1.5×10-5 g/m2 or more at a hydrogen pressure of 10MPa.

IPC Classes  ?

• C01B 31/02 - Preparation of carbon; Purification
• C01B 3/00 - HydrogenGaseous mixtures containing hydrogenSeparation of hydrogen from mixtures containing itPurification of hydrogen

Abstract

[Problem] To provide a near-field polarization microscope with which it is possible to accurately detect a magnetic domain in a sample while applying a magnetic field to the sample from the outside. [Solution] This near-field polarization microscope 1 is provided with: a cantilever 3 having a probe 2; a magnetic domain detection optical system 4 for detecting a magnetic domain in a sample 8 using near-field light produced by irradiating the probe 2 with a magnetic domain detection laser beam 11; an observation illumination optical system 5 for observing the state of irradiation by the magnetic domain detection laser beam 11; an objective lens 6 shared by the magnetic domain detection optical system 4 and the observation illumination optical system 5; and a magnetic field application means 7 for applying a magnetic field to the sample 8 from the outside. The cantilever 3, which is formed from a non-magnetic and electrically non-conductive material, and the sample 8, which is formed from a magnetic material, are arranged between an upper magnetic pole 43 and a lower magnetic pole 44 provided to the magnetic field application means 7.

IPC Classes  ?

• G01Q 60/18 - SNOM [Scanning Near-Field Optical Microscopy] or apparatus therefor, e.g. SNOM probes

Abstract

A method for detecting an inflammatory reaction characterized by comprising using a transformant or transgenic non-human animal, which carries a vector introduced thereinto, said vector comprising promoter of a gene encoding an inflammatory cytokine, a gene encoding a reporter protein, the gene encoding the aforesaid inflammatory cytokine and a gene encoding a protein decomposition signal sequence, and detecting the inflammatory reaction induced by an inflammatory stimulus in the aforesaid transformant or transgenic non-human animal.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

The present invention addresses the problem of providing an organic compound resistant to external environments such as high voltage or oxygen and usable as an electronic material or blue light-emitting element. This problem is solved by a coumalin condensed ring compound represented by general formula (1). In formula (1), R1-R4 each independently represent a hydrogen atom, a hydroxyl group, an alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a trialkylamino group, a trifluoromethyl group, a nitro group, or a cyano group, and Ar represents an aromatic ring or heteroaromatic ring which may have a substituent. When R1-R4 are all hydrogen atoms, Ar is not a benzene ring.

IPC Classes  ?

• C07D 311/78 - Ring systems having three or more relevant rings
• C07D 311/80 - DibenzopyransHydrogenated dibenzopyrans
• C07D 311/92 - NaphthopyransHydrogenated naphthopyrans
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)

Abstract

The present invention provides a method for manufacturing a carbon fiber precursor and a method for manufacturing a carbon fiber with which it is possible to perform infusibilization while maintaining a shape, and to reduce manufacturing costs and manufacture the carbon fiber cheaply. A vinyl polymer having, as a substituent, the conjugate base X of an acid HX in a side chain is made infusible by treating the vinyl polymer with an alkaline solution, and a carbon fiber precursor is produced. Also, a carbon fiber is produced by carbonizing this carbon fiber precursor by heat-treatment.

IPC Classes  ?

• D01F 9/21 - Carbon filamentsApparatus specially adapted for the manufacture thereof by decomposition of organic filaments from polyaddition, polycondensation or polymerisation products from macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds

Abstract

Disclosed herein is a porous film manufacturing method including: a heating step in which at least a part of a non-porous precursor film that includes a polyacetal resin is heated as a heated part; and a stretching step in which a porous film comprising a stretched part that was made porous by biaxially stretching the heated part of the precursor film is manufactured. In this manufacturing method: the heating step is at least performed in the stretching step; in the heating step, at least 5 mol of oxyalkylene units having two or more carbon atoms is added with respect to 100 mol of oxymethylene units in the polyacetal resin; the melt flow rate of the polyacetal resin is 0.1-30 g/10 minutes; and the heated part is heated at a temperature less than the melting point of the precursor film, and in the stretching step, the real biaxial stretch ratio, as defined in formula (1) below, is a value greater than 25 times in the stretch part of the precursor film. Real biaxial stretch ratio=dbefore/dafter… (1) (In formula (1), dbefore represents the thickness of the precursor film before the biaxial stretching, and dafter represents the minimum thickness of the stretched part of the precursor film after the biaxial stretching)

IPC Classes  ?

• C08J 9/00 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof

Abstract

This Plasmodium falciparum infection test drug and diagnostic drug contains a blocking agent and an antibody detection material which is obtained by reacting a crude antigen of Plasmodium falciparum and a polymer obtained by a polymeric reaction of a compound (I) and a compound (II), and which comprises an antigen protein derived from Plasmodium falciparum fixed on said polymer. (I) n indicates an integer 1-4. (II) X indicates a halogen or -0Y, and here, Y represents an alkyl group, an aromatic group, a pyridyl group, a quinolyl group, a succinimide group, maleimide group, a benzoxazole group, a benzothiazole group, or a benzotriazole group, and a hydrogen atom in these groups may be substituted with halogen.

IPC Classes  ?

• G01N 33/547 - Synthetic resin with antigen or antibody attached to the carrier via a bridging agent
• G01N 33/545 - Synthetic resin
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention uses an existing ultrasonic diagnostic device to obtain a color flow image of a target object that is to be measured for hardness. The present invention uses an excitation apparatus to apply to the target object micro-vibrations of a frequency that is n/4 (n being an odd number 1 or greater) times the burst frequency of an ultrasonic pulse and generates shear elastic waves. As a result of the shear elastic waves, a striped pattern that corresponds to the hardness of the target object appears as a shear elastic wave detection image on a display unit of the ultrasonic diagnostic device.

IPC Classes  ?

• A61B 8/08 - Clinical applications

Abstract

Provided is a production method for a carbon alloy catalyst, whereby an inexpensive catalyst having sufficient catalytic activity can be obtained. The production method uses at least either a Co or Fe compound as a metal compound, produces a carbon alloy catalyst, and includes at least: a step in which a thermoplastic resin and the metal compound are mixed; a step in which carbon black is added to the thermoplastic resin and metal compound mixture; an infusibilization step in which the thermoplastic resin is oxidized in an oxygen-containing atmosphere and infusibilized; and a step in which, after the infusibilization step, the thermoplastic resin is heat treated at 800-1,000°C and carbonized.

IPC Classes  ?

• B01J 23/745 - Iron
• B01J 37/04 - Mixing
• B01J 37/08 - Heat treatment
• B01J 37/14 - Oxidising with gases containing free oxygen

Abstract

　The present invention provides a therapeutic agent useful in the treatment and/or prevention of conditions, including cancer, caused by enhanced OPN production, the therapeutic agent containing a compound represented by the formula (in the formula, R1, R2, R3, R4, R5, R6, R7, m, n, p, X, and Y are as defined in the specification) or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07C 235/50 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/04 - Drugs for disorders of the urinary system for urolithiasis
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07C 233/36 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
• C07C 233/62 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
• C07C 233/78 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
• C07C 235/48 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
• C07C 235/60 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
• C07C 237/42 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
• C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
• C07D 213/81 - AmidesImides
• C07D 309/08 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Abstract

The present invention measures the expression level of CIDEC as an objective marker indicating the severity of depression. Furthermore, the present invention measures the combined expression level of one or more genes selected from the group comprising STYXL1, SLC36A1, RNASE1, ARFRP1, BCL11B, SLC35F2, BANP, RAB11FIP4, FYCO1, NIPAL3, RPL23A, RPS2 and SIGIRR. A test method for diagnosing and evaluating the severity of depression in test animals, a method for evaluating the efficacy of treatments for depression, and a method of screening therapeutic agents for depression are thus provided.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 37/00 - Details not covered by any other group of this subclass
• C12N 15/09 - Recombinant DNA-technology

Abstract

A non-human mammal capable of expressing a fusion protein in which two fluorescent proteins are bound respectively on an amino terminal side and a carboxy terminal side of an ε-subunit of an ATP synthetase, wherein the two fluorescent proteins can respectively serve as a donor and an accepter in fluorescence resonance energy transfer; and a method for screening for a medicinal agent, such as a prophylactic/therapeutic agent for various diseases, using the non-human mammal.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C12N 15/09 - Recombinant DNA-technology

Abstract

　Provided is a spacer that can be placed in a body and can be removed easily after placement. An implantable spacer is provided with: a tube folded or bent at one or a plurality of locations, the tube forming mutually adjacent subspaces; fixation threads provided along a direction transverse to the subspaces in order to maintain the shape of the tube; and trigger threads for locking the fixation threads in a releasable state.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

Provided is a reagent for measuring oxygen concentration, the reagent having low toxicity to a spheroid. Also provided is a method that uses the reagent and is for measuring the oxygen concentration in a spheroid. A reagent for measuring the oxygen concentration inside a spheroid, the reagent containing C-cis,N-trans,bis[2-(2'-benzothienyl)-pyridinato-N,C3']iridium(acetylacetonate). A method for measuring the oxygen concentration in a spheroid, the method including (a) a step for culturing cells on a culture substrate that is capable of forming a spheroid, (b) a step for bringing the cells into contact with C-cis,N-trans,bis[2-(2'-benzothienyl)-pyridinato-N,C3']iridium(acetylacetonate), and (c) a step for evaluating the oxygen concentration inside a spheroid using changes in phosphorescence as an index.

IPC Classes  ?

• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 21/64 - FluorescencePhosphorescence
• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
• G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods